Windlas Biotech Limited IPO (Windlas Biotech IPO) Detail - Ajay Singh Chauhan

Windlas Biotech Limited IPO (Windlas Biotech IPO) Detail

Incorporated in 2001, Windlas Biotech Ltd is one of the main agencies within the pharmaceutical formulations settlement improvement and production groups (CDMO) phase in India. The business enterprise offers a variety of CDMO services from product discovery to product improvement, licensing, and industrial production of universal products such as complex generics.

It in addition sells its very own branded merchandise inside the exchange generics and OTC markets. Currently, the point of interest of the business enterprise is to launch complex popular merchandise within the continual healing class associated with lifestyle-associated issues. The enterprise operates in 3 verticals; 1. CDMO Products and offerings, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and fitness supplement products), and 3. Export.

Leading pharma corporations i.E. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are a number of the marquee clients of Windlas Biotech. Its manufacturing centers are located at Dehradun with an established working capacity of 7,063.83 million capsules/ tablets, 54.Forty six million pouch/ sachet, and 61.08 million liquid bottles.

Competitive strengths

Leading marketplace player inside the home pharmaceutical components CDMO phase.
Strong focus on the continual healing class.
Cutting-edge manufacturing facilities in Dehradun, Uttarakhand.
Professional and skilled Promoters and a senior management group.
An progressive product portfolio of complex established products.
Robust economic overall performance song report.


Company Promoters:
Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt Trust are the employer promoters.

Company Financials:

ParticularsFor the year/period ended (₹ in million)
31-Dec-2031-Mar-2031-Mar-1931-Mar-18
Total Assets3,158.833,384.882,981.802,898.87
Total Revenue3,230.943,313.393,115.253,565.76
Profit After Tax96.74162.13638.22111.98

Objects of the Issue:

  • To purchase equipment required for capacity expansion of our existing facility at Dehradun Plant IV.
  • To finance incremental working capital requirements of the company.
  • Repayment/prepayment of company’s borrowings.
  • General corporate purposes.

Windlas Biotech IPO Details

IPO Opening DateAug 4, 2021
IPO Closing DateAug 6, 2021
Issue TypeBook Built Issue IPO
Face Value₹5 per equity share
IPO Price₹448 to ₹460 per equity share
Market Lot30 Shares
Min Order Quantity30 Shares
Listing AtBSE, NSE
Issue Size[.] Eq Shares of ₹5
(aggregating up to ₹401.54 Cr)
Fresh Issue[.] Eq Shares of ₹5
(aggregating up to ₹165.00 Cr)
Offer for Sale5,142,067 Eq Shares of ₹5
(aggregating up to ₹236.54 Cr)

Windlas Biotech IPO Tentative Timetable

The Windlas Biotech IPO open date is Aug 4, 2021, and the close date is Aug 6, 2021. The issue may list on Aug 17, 2021.

IPO Open DateAug 4, 2021
IPO Close DateAug 6, 2021
Basis of Allotment DateAug 11, 2021
Initiation of RefundsAug 12, 2021
Credit of Shares to Demat AccountAug 13, 2021
IPO Listing DateAug 17, 2021

Windlas Biotech IPO Lot Size

The Windlas Biotech IPO market lot size is 30 shares. A retail-individual investor can apply for up to 14 lots (420 shares or ₹193,200).

ApplicationLotsSharesAmount (Cut-off)
Minimum130₹13,800
Maximum14420₹193,200

Windlas Biotech IPO Promoter Holding

Pre Issue Share Holding78%
Post Issue Share Holding65.16%

Windlas Biotech IPO Registrar

Link Intime India Private Ltd
   Link Intime India Private Ltd
   C 101, 247 Park, L.B.S.Marg,
   Vikhroli (West), Mumbai – 400083

Phone: +91-22-4918 6270
Email: [email protected]
Websitehttp://www.linkintime.co.in

Leave a Reply

Your email address will not be published. Required fields are marked *